摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-4-氯吲唑 | 885518-99-0

中文名称
6-溴-4-氯吲唑
中文别名
6-溴-4-氯-1H-吲唑
英文名称
6-bromo-4-chloro-1H-indazole
英文别名
——
6-溴-4-氯吲唑化学式
CAS
885518-99-0
化学式
C7H4BrClN2
mdl
——
分子量
231.479
InChiKey
MOYPLQILACEGCD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    364.1±22.0 °C(Predicted)
  • 密度:
    1.878

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P280,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥

SDS

SDS:c4700d310cdc73e4c8389151cf508e28
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-4-chloro-1H-indazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-4-chloro-1H-indazole
CAS number: 885518-99-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrClN2
Molecular weight: 231.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

6-溴-4-氯吲唑是一种含有两个卤素原子的有机化合物,其强大的抗真菌活性正是由于这些卤素原子的存在。通过作用于真菌细胞膜和细胞壁,这种化合物能有效抑制真菌的生长与繁殖。

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
    摘要:
    A novel sulfonylureido pyridine series exemplified by compound 19 yielded potent inhibitors of FBPase showing significant glucose reduction and modest glycogen lowering in the acute db/db mouse model for Type-2 diabetes. Our inhibitors occupy the allosteric binding site and also extend into the dyad interface region of tetrameric FBPase. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.04.044
点击查看最新优质反应信息

文献信息

  • PYRIDIN-2-ONE DERIVATIVES OF FORMULA (I) USEFUL AS EP3 RECEPTOR ANTAGONISTS
    申请人:Janssen Pharmaceutica NV
    公开号:US20190047959A1
    公开(公告)日:2019-02-14
    The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.
    本发明涉及吡啶-2-酮衍生物,包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用,用于治疗例如受损的口服葡萄糖耐量、空腹血糖升高、2型糖尿病、综合征X(也称为代谢综合征)及其相关疾病和并发症。
  • PYRIDIN-2-ONE DERIVATIVES OF FORMULA (III) USEFUL AS EP3 RECEPTOR ANTAGONISTS
    申请人:Janssen Pharmaceutica NV
    公开号:US20190047961A1
    公开(公告)日:2019-02-14
    The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.
    本发明涉及吡啶-2-酮衍生物,包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用,用于治疗例如受损的口服葡萄糖耐量,空腹血糖升高,2型糖尿病,综合征X(也称为代谢综合征)以及与之相关的疾病和并发症。
  • [EN] POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS<br/>[FR] COMPOSÉS POLYCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS ALLOSTÉRIQUES DE SHP2
    申请人:REVOLUTION MEDICINES INC
    公开号:WO2019118909A1
    公开(公告)日:2019-06-20
    The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    本公开涉及SHP2的抑制剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。
  • PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS
    申请人:Janssen Pharmaceutica NV
    公开号:US20190047960A1
    公开(公告)日:2019-02-14
    The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.
    本发明涉及吡啶-2-酮衍生物,包含它们的药物组合物以及它们作为EP3受体的拮抗剂的使用,用于治疗例如受损的口服葡萄糖耐量,空腹血糖升高,2型糖尿病,综合征X(也称为代谢综合征)以及与之相关的疾病和并发症。
  • [EN] PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES PYRAZOLO ET TRIAZOLO UTILISÉS EN TANT QU'INHIBITEURS DE KINASE JAK
    申请人:THERAVANCE BIOPHARMA R&D IP LLC
    公开号:WO2019027960A1
    公开(公告)日:2019-02-07
    The invention provides compounds of formula (I) or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    这项发明提供了式(I)的化合物或其药用可接受的盐,其中变量在规范中定义,这些化合物是JAK激酶的抑制剂,特别是JAK3。该发明还提供了结晶形式,包含这些化合物的药物组合物,使用这些化合物治疗胃肠道和其他炎症性疾病的方法,以及用于制备这些化合物的工艺和中间体。
查看更多